AR032153A1 - Derivados de acidos poliamidonucleicos, agentes y procedimientos para su preparacion; medicamento, procedimiento para su preparacion, reactivo de deteccion, procedimiento para su preparacion, chip de pna, biosensor, agente anti-sentido y su procedimiento de preparacion, y empleo de dichos derivados - Google Patents
Derivados de acidos poliamidonucleicos, agentes y procedimientos para su preparacion; medicamento, procedimiento para su preparacion, reactivo de deteccion, procedimiento para su preparacion, chip de pna, biosensor, agente anti-sentido y su procedimiento de preparacion, y empleo de dichos derivadosInfo
- Publication number
- AR032153A1 AR032153A1 ARP010101766A ARP010101766A AR032153A1 AR 032153 A1 AR032153 A1 AR 032153A1 AR P010101766 A ARP010101766 A AR P010101766A AR P010101766 A ARP010101766 A AR P010101766A AR 032153 A1 AR032153 A1 AR 032153A1
- Authority
- AR
- Argentina
- Prior art keywords
- equal
- group
- independently
- radical
- preparation
- Prior art date
Links
- 238000000034 method Methods 0.000 title 4
- 238000002360 preparation method Methods 0.000 title 4
- 239000003795 chemical substances by application Substances 0.000 title 2
- 239000002253 acid Substances 0.000 title 1
- 150000007513 acids Chemical class 0.000 title 1
- 230000000692 anti-sense effect Effects 0.000 title 1
- 239000003153 chemical reaction reagent Substances 0.000 title 1
- 238000001514 detection method Methods 0.000 title 1
- 229940079593 drug Drugs 0.000 title 1
- 239000003814 drug Substances 0.000 title 1
- 229910052739 hydrogen Inorganic materials 0.000 abstract 7
- 239000001257 hydrogen Substances 0.000 abstract 7
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 7
- -1 hydroxy, mercapto, amino Chemical group 0.000 abstract 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 abstract 5
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 abstract 4
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 abstract 4
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 abstract 4
- DZBUGLKDJFMEHC-UHFFFAOYSA-N acridine Chemical compound C1=CC=CC2=CC3=CC=CC=C3N=C21 DZBUGLKDJFMEHC-UHFFFAOYSA-N 0.000 abstract 4
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract 4
- 229910052760 oxygen Inorganic materials 0.000 abstract 4
- 239000001301 oxygen Substances 0.000 abstract 4
- ZCCUUQDIBDJBTK-UHFFFAOYSA-N psoralen Chemical compound C1=C2OC(=O)C=CC2=CC2=C1OC=C2 ZCCUUQDIBDJBTK-UHFFFAOYSA-N 0.000 abstract 4
- BBEAQIROQSPTKN-UHFFFAOYSA-N pyrene Chemical compound C1=CC=C2C=CC3=CC=CC4=CC=C1C2=C43 BBEAQIROQSPTKN-UHFFFAOYSA-N 0.000 abstract 4
- 229910052717 sulfur Inorganic materials 0.000 abstract 4
- 239000011593 sulfur Substances 0.000 abstract 4
- 125000003396 thiol group Chemical group [H]S* 0.000 abstract 4
- MJYFVDNMTKLGTH-UHFFFAOYSA-N 4-bromo-6-(3,4-dichlorophenyl)sulfanyl-1-[[4-(dimethylcarbamoyl)phenyl]methyl]indole-2-carboxylic acid Chemical compound BrC1=C2C=C(N(C2=CC(=C1)SC1=CC(=C(C=C1)Cl)Cl)CC1=CC=C(C=C1)C(N(C)C)=O)C(=O)O MJYFVDNMTKLGTH-UHFFFAOYSA-N 0.000 abstract 3
- 125000000217 alkyl group Chemical group 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- VXGRJERITKFWPL-UHFFFAOYSA-N 4',5'-Dihydropsoralen Natural products C1=C2OC(=O)C=CC2=CC2=C1OCC2 VXGRJERITKFWPL-UHFFFAOYSA-N 0.000 abstract 2
- QUHGSDZVAPFNLV-UHFFFAOYSA-N 4-[(5-acetamidofuran-2-carbonyl)amino]-n-[3-(dimethylamino)propyl]-1-propylpyrrole-2-carboxamide Chemical compound C1=C(C(=O)NCCCN(C)C)N(CCC)C=C1NC(=O)C1=CC=C(NC(C)=O)O1 QUHGSDZVAPFNLV-UHFFFAOYSA-N 0.000 abstract 2
- SHIBSTMRCDJXLN-UHFFFAOYSA-N Digoxigenin Natural products C1CC(C2C(C3(C)CCC(O)CC3CC2)CC2O)(O)C2(C)C1C1=CC(=O)OC1 SHIBSTMRCDJXLN-UHFFFAOYSA-N 0.000 abstract 2
- 229930003427 Vitamin E Natural products 0.000 abstract 2
- 238000010521 absorption reaction Methods 0.000 abstract 2
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 abstract 2
- 125000003275 alpha amino acid group Chemical group 0.000 abstract 2
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 2
- 230000001588 bifunctional effect Effects 0.000 abstract 2
- 229960002685 biotin Drugs 0.000 abstract 2
- 235000020958 biotin Nutrition 0.000 abstract 2
- 239000011616 biotin Substances 0.000 abstract 2
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol group Chemical group [C@@H]1(CC[C@H]2[C@@H]3CC=C4C[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)[C@H](C)CCCC(C)C HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 abstract 2
- 238000004132 cross linking Methods 0.000 abstract 2
- QONQRTHLHBTMGP-UHFFFAOYSA-N digitoxigenin Natural products CC12CCC(C3(CCC(O)CC3CC3)C)C3C11OC1CC2C1=CC(=O)OC1 QONQRTHLHBTMGP-UHFFFAOYSA-N 0.000 abstract 2
- SHIBSTMRCDJXLN-KCZCNTNESA-N digoxigenin Chemical compound C1([C@@H]2[C@@]3([C@@](CC2)(O)[C@H]2[C@@H]([C@@]4(C)CC[C@H](O)C[C@H]4CC2)C[C@H]3O)C)=CC(=O)OC1 SHIBSTMRCDJXLN-KCZCNTNESA-N 0.000 abstract 2
- GVEPBJHOBDJJJI-UHFFFAOYSA-N fluoranthrene Natural products C1=CC(C2=CC=CC=C22)=C3C2=CC=CC3=C1 GVEPBJHOBDJJJI-UHFFFAOYSA-N 0.000 abstract 2
- GNBHRKFJIUUOQI-UHFFFAOYSA-N fluorescein Chemical compound O1C(=O)C2=CC=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 GNBHRKFJIUUOQI-UHFFFAOYSA-N 0.000 abstract 2
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 abstract 2
- 150000002431 hydrogen Chemical class 0.000 abstract 2
- 230000003834 intracellular effect Effects 0.000 abstract 2
- 108700009084 lexitropsin Proteins 0.000 abstract 2
- 239000003550 marker Substances 0.000 abstract 2
- 150000007523 nucleic acids Chemical class 0.000 abstract 2
- 102000039446 nucleic acids Human genes 0.000 abstract 2
- 108020004707 nucleic acids Proteins 0.000 abstract 2
- ABZLKHKQJHEPAX-UHFFFAOYSA-N tetramethylrhodamine Chemical compound C=12C=CC(N(C)C)=CC2=[O+]C2=CC(N(C)C)=CC=C2C=1C1=CC=CC=C1C([O-])=O ABZLKHKQJHEPAX-UHFFFAOYSA-N 0.000 abstract 2
- ANRHNWWPFJCPAZ-UHFFFAOYSA-M thionine Chemical compound [Cl-].C1=CC(N)=CC2=[S+]C3=CC(N)=CC=C3N=C21 ANRHNWWPFJCPAZ-UHFFFAOYSA-M 0.000 abstract 2
- 229940046009 vitamin E Drugs 0.000 abstract 2
- 235000019165 vitamin E Nutrition 0.000 abstract 2
- 239000011709 vitamin E Substances 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- AFCIMSXHQSIHQW-UHFFFAOYSA-N [O].[P] Chemical compound [O].[P] AFCIMSXHQSIHQW-UHFFFAOYSA-N 0.000 abstract 1
- QCJQWJKKTGJDCM-UHFFFAOYSA-N [P].[S] Chemical compound [P].[S] QCJQWJKKTGJDCM-UHFFFAOYSA-N 0.000 abstract 1
- 125000004442 acylamino group Chemical group 0.000 abstract 1
- 125000003545 alkoxy group Chemical group 0.000 abstract 1
- 125000003282 alkyl amino group Chemical group 0.000 abstract 1
- 210000004899 c-terminal region Anatomy 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 229910052799 carbon Inorganic materials 0.000 abstract 1
- 125000001072 heteroaryl group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- 239000002773 nucleotide Substances 0.000 abstract 1
- 125000003729 nucleotide group Chemical group 0.000 abstract 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 abstract 1
- 229940002612 prodrug Drugs 0.000 abstract 1
- 239000000651 prodrug Substances 0.000 abstract 1
- PYWVYCXTNDRMGF-UHFFFAOYSA-N rhodamine B Chemical compound [Cl-].C=12C=CC(=[N+](CC)CC)C=C2OC2=CC(N(CC)CC)=CC=C2C=1C1=CC=CC=C1C(O)=O PYWVYCXTNDRMGF-UHFFFAOYSA-N 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000006850 spacer group Chemical group 0.000 abstract 1
- 150000003413 spiro compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/001—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof by chemical synthesis
- C07K14/003—Peptide-nucleic acids (PNAs)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
- Y10T436/00—Chemistry: analytical and immunological testing
- Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
- Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
- Y10T436/143333—Saccharide [e.g., DNA, etc.]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Genetics & Genomics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Biophysics (AREA)
- Dermatology (AREA)
- Tropical Medicine & Parasitology (AREA)
- AIDS & HIV (AREA)
- Biotechnology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Polyamides (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Investigating Or Analysing Materials By The Use Of Chemical Reactions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Derivados de PNA, que lleva en el terminal de C o en el terminal de C y de N del esqueleto de PNA uno o varios radicales fosforilo, que incluye además junto a radicales oxo-, también radicales tio- e imino-fosforilo, y en el cual por lo menos uno de los radicales fosforilo lleva uno o varios grupos desprotonizables, preferentemente grupos hidroxilo o mercapto, estando unidos los radicales fosforilo a través de un enlace oxígeno-fosforo, azufre-fosforo o nitrogeno-fosforo ya sea directamente o bien a través de un espaciador con el esqueleto de PNA. Derivado de PNA caracterizado porque comprende la formula (1), en la cual q es igual a 0 o 1; D' es igual a hidroxilo, mercapto, amino, alquilamino o acilamino; V independiente entre sí es igual a oxígeno, azufre, NR1; V' independiente entre sí es igual a oxígeno, azufre, NR1, un grupo U-(CR3R4)u'-C(O)-NH o un grupo U-(CH2CH2O)u'-CH2-C(O)-NH; U independientemente entre sí es igual a oxígeno, azufre o NH; u' independientemente entre sí es igual a de 1 a 10, preferentemente de 1 a 4, de modo particularmente preferido 1; W y W' independiente entre sí son iguales a oxígeno, azufre, NR1; Y e Y' independiente entre sí son iguales a hidroxilo, mercapto, oxianion, tioato o NR1R2; X y X' independiente entre sí son iguales a un grupo U-(C2-22-alcanodiíl)-U o un grupo U-(CH2-CH2-O)u' o a un grupo marcador, o a un grupo para el entrecruzamiento, o a un grupo que favorece la absorcion intracelular, o un grupo que aumenta la afinidad de union del derivado de PNA con ácidos nucleicos, por ejemplo, un radical bifuncional de fluoresceína, de rodamina, de TAMRA, de biotina, de pireno, de dinitrofenilo, de colesterilo, de acridina, de adamantilo, de vitamina E, de colorante de cianina, de dabcilo, de edans, de lexitropsina, de psoraleno, de BODIPY, de ROX, de R6G, o de digoxigenina; Z y Z' independientemente entre sí son iguales a hidroxilo, mercapto, oxianion, tioato, o NR1R2, alquilo-C1-22, arilalquilo-C1-8, alquil-C1-22-U, arilalquil-C1-8-U, hidroxi-C1-18-U, aminoalquil-U, mercaptoalquil-U, o es un grupo de la formula R7(CH2CH2-O)m, en la cual R7 es igual a hidroxilo, amino o alcoxilo-C1-22 y m es igual a de 1 a 100 preferentemente de 2 a 10, o es igual a un grupo marcador, o un grupo para el entrecruzamiento, o a un grupo que favorece la absorcion intracelular, o un grupo que aumenta la afinidad de union del derivado de PNA con ácidos nucleicos, por ejemplo, un radical monofuncional o bifuncional de fluoresceína, derodamina, de TAMRA, de biotina, de pireno, de dinitrofenilo, de colesterilo, de acridina, de adamantilo, de vitamina E, de colorante de cianina, de dabcilo, de edans, de lexitropsina, de psoraleno, de BODIPY, de ROX, de R6G, o de digoxigenina; R1 y R2 independientemente entre sí significan un radical que consiste en hidrogeno o alquilo-C1-6, preferentemente hidrogeno; R3 y R4 independientemente entre sí significan un radical que consiste en hidrogeno o alquilo-C1-6 o el radical de una cadena lateral de aminoácido, preferentemente hidrogeno, pudiendo formar radicales vecinos R3 y R4 en V' también un anillo de cicloalquilo-C5-8; n es igual a de 0 a 10, preferentemente de 0 a 3; m es igual a de 0 a 10, preferentemente de 0 a 3; y en la cual el grupo (POLY) se describe mediante la formula (2), en la cual además (BLOCK), independientemente entre sí, es un grupo seleccionado de la formula (3), o de la formula (4), o de las formulas (5) a (11) pudiendo ser cada modulo (BLOCK) diferente, siendo además válido que z'' es igual a de 0 a 100, preferentemente 1-20 de modo particularmente preferido 4-15; G se seleccciona de los grupos (CR5R6)u', C(O)NH-(CR1R2)t' o C(O)NH-(CH2CH2O)u'-CH2-CH2, en los cuales u' tiene el significado anterior y t' es igual a de 2 a 10, preferentemente 6; A independientemente entre sí es un grupo (CR1R2)s' en la cual s es igual a de 1 a 3, preferentemente 1; B independientemente entre sí es o bien un radical aromático, que también puede poseer carácter heteroaromático, o hidrogeno, o hidroxilo o alquilo-C1-18, o bien es una nucleobase que aparece usualmente de manera natural en la química de los nucleotidos o una nucleobase que no se da naturalmente o su forma de profármaco; D independientemente entre sí es un grupo (CR3R4)t, en la cual t es igual a de 2 a 10, preferentemente de 2 a 4, de modo particularmente preferido 2; E independientemente entre sí es un grupo (CR5R6)u', pudiendo formar radicales R5 y R6 vecinos también un anillo de cicloalquilo-C5-8 o un espirocompuesto, R5 y R6 independientemente entre sí significan un radical que consiste en hidrogeno o alquilo-C1-6 o el radical de una cadena lateral de aminoácido, preferentemente hidrogeno; así como las sales fisiologicamente tolerables de los derivados de PNA de la formula (1), con la condicion de que por lo menos un radical Y, Y', Z, o Z' es igual a hidroxilo, mercapto, oxianion o tioato y que por lo menos un radical B es una nucleobase. Empleo de derivados de PNA contra el cáncer.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE10019135A DE10019135A1 (de) | 2000-04-18 | 2000-04-18 | Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR032153A1 true AR032153A1 (es) | 2003-10-29 |
Family
ID=7639143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP010101766A AR032153A1 (es) | 2000-04-18 | 2001-04-16 | Derivados de acidos poliamidonucleicos, agentes y procedimientos para su preparacion; medicamento, procedimiento para su preparacion, reactivo de deteccion, procedimiento para su preparacion, chip de pna, biosensor, agente anti-sentido y su procedimiento de preparacion, y empleo de dichos derivados |
Country Status (21)
| Country | Link |
|---|---|
| US (5) | US6905820B2 (es) |
| EP (1) | EP1276760B1 (es) |
| JP (1) | JP4908714B2 (es) |
| KR (1) | KR100842723B1 (es) |
| AR (1) | AR032153A1 (es) |
| AT (1) | ATE344276T1 (es) |
| AU (1) | AU5479501A (es) |
| BR (1) | BR0110110A (es) |
| CA (1) | CA2406169C (es) |
| CY (1) | CY1105958T1 (es) |
| DE (2) | DE10019135A1 (es) |
| DK (1) | DK1276760T3 (es) |
| ES (1) | ES2275677T3 (es) |
| IL (2) | IL152288A0 (es) |
| MX (1) | MXPA02009953A (es) |
| NO (1) | NO333193B1 (es) |
| NZ (1) | NZ521988A (es) |
| PT (1) | PT1276760E (es) |
| TW (1) | TWI298328B (es) |
| WO (1) | WO2001079216A2 (es) |
| ZA (1) | ZA200208344B (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6518017B1 (en) * | 1997-10-02 | 2003-02-11 | Oasis Biosciences Incorporated | Combinatorial antisense library |
| US20030165888A1 (en) | 2001-07-18 | 2003-09-04 | Brown Bob D. | Oligonucleotide probes and primers comprising universal bases for diagnostic purposes |
| AU777910B2 (en) * | 1999-04-08 | 2004-11-04 | Gen-Probe Incorporated | Amplification and sequencing primer pairs and use thereof |
| DE10019135A1 (de) * | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung |
| TWI286849B (en) * | 2003-03-25 | 2007-09-11 | Nichia Corp | Positive electrode active material for nonaqueous electrolyte secondary battery and nonaqueous electrolyte secondary battery |
| EP2160607B1 (en) * | 2007-05-31 | 2011-09-07 | Sanofi | Assay methods for identifying agents that modify the activity of nape-pld or abh4 |
| WO2009044403A2 (en) * | 2007-10-05 | 2009-04-09 | Juvenis Ltd. | Injectable biodegradable polymer compositions for soft tissue repair and augmentation |
| US20090276412A1 (en) * | 2008-04-30 | 2009-11-05 | Nokia Corporation | Method, apparatus, and computer program product for providing usage analysis |
| US20090276436A1 (en) * | 2008-04-30 | 2009-11-05 | Nokia Corporation | Method, apparatus, and computer program product for providing service invitations |
| US20090276855A1 (en) * | 2008-04-30 | 2009-11-05 | Nokia Corporation | Method, apparatus, and computer program product that provide for presentation of event items |
| US20090276700A1 (en) * | 2008-04-30 | 2009-11-05 | Nokia Corporation | Method, apparatus, and computer program product for determining user status indicators |
| US20090292762A1 (en) * | 2008-05-20 | 2009-11-26 | Nokia Corporation | Method, Apparatus, and Computer Program Product for Publishing Content |
| US20090327434A1 (en) * | 2008-06-30 | 2009-12-31 | Nokia Corporation | Method, Apparatus, and Computer Program Product for Anonymous Polling |
| USD696048S1 (en) * | 2010-08-12 | 2013-12-24 | Sealy Technology, Llc | Mattress |
| JP5990987B2 (ja) * | 2012-04-11 | 2016-09-14 | 株式会社Ihi | 微生物固定方法、および微生物検出方法 |
| JP2015172904A (ja) * | 2014-03-12 | 2015-10-01 | 株式会社東芝 | Ｌｄｏ型電圧レギュレータ、及び、受電装置 |
| WO2016123244A1 (en) * | 2015-01-27 | 2016-08-04 | Indicator Systems International, Inc. | Fluorescein polymer conjugates |
| KR102659194B1 (ko) * | 2016-07-26 | 2024-04-19 | 삼성전자주식회사 | 홀로그래픽 디스플레이 장치용 박형 백라이트 유닛 및 이를 포함하는 홀로그래픽 디스플레이 장치 |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ATE192465T1 (de) * | 1987-10-28 | 2000-05-15 | Florey Howard Inst | Oligonucleotid-polyamid konjugate |
| DK51092D0 (da) | 1991-05-24 | 1992-04-15 | Ole Buchardt | Oligonucleotid-analoge betegnet pna, monomere synthoner og fremgangsmaade til fremstilling deraf samt anvendelser deraf |
| ZA951877B (en) * | 1994-03-07 | 1996-09-09 | Dow Chemical Co | Bioactive and/or targeted dendrimer conjugates |
| DE4408531A1 (de) * | 1994-03-14 | 1995-09-28 | Hoechst Ag | PNA-Synthese unter Verwendung einer gegen schwache Säuren labilen Amino-Schutzgruppe |
| DE4408528A1 (de) | 1994-03-14 | 1995-09-28 | Hoechst Ag | Peptid-Oligonucleotid-Derivate, deren Herstellung und Verwendung |
| WO1996011205A1 (en) * | 1994-10-06 | 1996-04-18 | Isis Pharmaceuticals, Inc. | Peptide nucleic acid conjugates |
| DE19508923A1 (de) * | 1995-03-13 | 1996-09-19 | Hoechst Ag | Phosphonomonoesternukleinsäuren, Verfahren zu ihrer Herstellung und ihre Verwendung |
| PT739898E (pt) | 1995-03-13 | 2002-03-28 | Aventis Pharma Gmbh | Mono-esteres de acidos fosfonucleicos processo para a sua preparacao e sua utilizacao |
| DE19640974A1 (de) | 1996-10-04 | 1998-04-16 | Bayer Ag | Bausteine für DNA/PNA-Cooligomere |
| DE19757516A1 (de) * | 1997-12-23 | 1999-06-24 | Roche Diagnostics Gmbh | Modifizierte Nukleinsäureanaloga |
| US6326479B1 (en) * | 1998-01-27 | 2001-12-04 | Boston Probes, Inc. | Synthetic polymers and methods, kits or compositions for modulating the solubility of same |
| US6043352A (en) * | 1998-08-07 | 2000-03-28 | Isis Pharmaceuticals, Inc. | 2'-O-Dimethylaminoethyloxyethyl-modified oligonucleotides |
| DE10019136A1 (de) * | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung |
| DE10019135A1 (de) * | 2000-04-18 | 2001-10-31 | Aventis Pharma Gmbh | Polyamidnukleinsäure-Derivate, Mittel und Verfahren zu ihrer Herstellung |
-
2000
- 2000-04-18 DE DE10019135A patent/DE10019135A1/de not_active Ceased
-
2001
- 2001-04-07 IL IL15228801A patent/IL152288A0/xx unknown
- 2001-04-07 EP EP01927897A patent/EP1276760B1/de not_active Expired - Lifetime
- 2001-04-07 DE DE50111371T patent/DE50111371D1/de not_active Expired - Lifetime
- 2001-04-07 BR BR0110110-2A patent/BR0110110A/pt not_active IP Right Cessation
- 2001-04-07 KR KR1020027013932A patent/KR100842723B1/ko not_active Expired - Fee Related
- 2001-04-07 AU AU5479501A patent/AU5479501A/xx not_active Withdrawn
- 2001-04-07 AT AT01927897T patent/ATE344276T1/de active
- 2001-04-07 NZ NZ521988A patent/NZ521988A/xx not_active IP Right Cessation
- 2001-04-07 MX MXPA02009953A patent/MXPA02009953A/es active IP Right Grant
- 2001-04-07 ES ES01927897T patent/ES2275677T3/es not_active Expired - Lifetime
- 2001-04-07 PT PT01927897T patent/PT1276760E/pt unknown
- 2001-04-07 DK DK01927897T patent/DK1276760T3/da active
- 2001-04-07 CA CA2406169A patent/CA2406169C/en not_active Expired - Fee Related
- 2001-04-07 JP JP2001576814A patent/JP4908714B2/ja not_active Expired - Fee Related
- 2001-04-07 WO PCT/EP2001/004030 patent/WO2001079216A2/de not_active Ceased
- 2001-04-16 AR ARP010101766A patent/AR032153A1/es unknown
- 2001-04-17 US US09/835,371 patent/US6905820B2/en not_active Expired - Fee Related
- 2001-05-16 TW TW090108986A patent/TWI298328B/zh not_active IP Right Cessation
-
2002
- 2002-10-14 IL IL152288A patent/IL152288A/en not_active IP Right Cessation
- 2002-10-15 NO NO20024959A patent/NO333193B1/no not_active IP Right Cessation
- 2002-10-16 ZA ZA200208344A patent/ZA200208344B/en unknown
-
2004
- 2004-06-02 US US10/858,658 patent/US20050009073A1/en not_active Abandoned
-
2007
- 2007-01-29 CY CY20071100108T patent/CY1105958T1/el unknown
- 2007-09-14 US US11/855,443 patent/US7550582B2/en not_active Expired - Fee Related
-
2009
- 2009-05-29 US US12/474,532 patent/US7897346B2/en not_active Expired - Fee Related
-
2011
- 2011-01-24 US US13/012,266 patent/US8268560B2/en not_active Expired - Fee Related
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR032153A1 (es) | Derivados de acidos poliamidonucleicos, agentes y procedimientos para su preparacion; medicamento, procedimiento para su preparacion, reactivo de deteccion, procedimiento para su preparacion, chip de pna, biosensor, agente anti-sentido y su procedimiento de preparacion, y empleo de dichos derivados | |
| PT693065E (pt) | Derivados de cumarina nao-nucleosidicos como agentes reticulantes de polionucleotidos | |
| ES2281368T3 (es) | Derivados de carbamato hidroliticamente degradables de poli(etilenglicol). | |
| BR0007781A (pt) | Conjugado fisiologicamente ativo, composição, e, processo para a produção de um conjugado de peg-gcsf | |
| Hecht et al. | Porphyrin core star polymers: synthesis, modification, and implication for site isolation | |
| SV2002000120A (es) | Derivados de eritropoyetina caso 20431 | |
| EP2183266A2 (en) | Modified nucleotides, methods for making and using same | |
| BRPI0012138B8 (pt) | conjugado, composição que compreende conjugados, composição farmacêutica, uso de um conjugado ou uma composição e processo para a preparação de um conjugado ou uma composição | |
| AR030210A1 (es) | Derivados de acidos poliamidonucleicos, procedimientos para su preparacion, medicamento, procedimiento para su preparacion, chip de dna, procedimiento para su preparacion,reactivo de deteccion, biosensor, medicamento y empleo de dichos derivados para la preparacion de un medicamento, reactivo de det | |
| AR043084A1 (es) | Un metodo para preparar un complejo de cisplatino | |
| ES2185769T3 (es) | Oxidos de polietileno con un resto sacarido en un extremo y un grupo funcional diferente en el otro extremo y procedimientos de produccion de los mismos. | |
| CA2524907A1 (en) | Polyethylene glycol/polycation block copolymers | |
| AR016001A1 (es) | Uso de polimeros de amina alifatica para la fabricacion de medicamentos para la reduccion de niveles de oxalato en un paciente | |
| ES2078313T3 (es) | Sales de n,n'-(1-oxo-1,2-etanodiil)-bis(acido aspartico) y uso en composiciones detergentes. | |
| ES2164265T3 (es) | Unidades monomericas utiles para reducir el modulo de hidrogeles de silicona. | |
| ES2151185T3 (es) | Lipopoliaminas como agentes de transfeccion y sus aplicaciones farmaceuticas. | |
| ES2168479T3 (es) | Compuestos de ciclopentano sustituidos heterociclicos. | |
| KR900009725A (ko) | 화합물 | |
| AR029158A1 (es) | Composicion y metodo para mejorar la estabilidad de la viscosidad de composiciones acuosas | |
| BR9505196A (pt) | Tenso ativo de silicone espuma de poliuretano e processo para a produçao de espuma de poliuretano | |
| ES2174958T3 (es) | Mejoras introducidas en agentes de contraste. | |
| KR960017621A (ko) | 신남산 유도체 | |
| ATE283858T1 (de) | Verbindungen zur pdt | |
| KR930016438A (ko) | 비뉴클레오티드성 그룹을 갖는 3'-유도된 올리고뉴클레오티드 유사체, 이의 제조방법 및 용도 | |
| BR9906441A (pt) | Agente e processo para a obtenção de tingimentos temporários sobre fibras de queratina |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |